Showing results (71-80 of 81) with videos related to

Sort By:
Pageof 9
Japanese Journal of Clinical Oncology|February 12, 2008
Report of AIDS-related lymphoma in South KoreaJin-Soo Kim, Seok Jin Kim, Jin-Seok Kim, et al.
Cancer Research and Treatment|September 14, 2016
An Open-Label, Randomized, Parallel, Phase III Trial Evaluating the Efficacy and Safety of Polymeric Micelle-Formulated Paclitaxel Compared to Conventional Cremophor EL-Based Paclitaxel for Recurrent or Metastatic HER2-Negative Breast CancerIn Hae Park, Joo Hyuk Sohn, Sung Bae Kim, et al.
British Journal of Haematology|February 26, 2013
Comparative analysis between azacitidine and decitabine for the treatment of myelodysplastic syndromesYun-Gyoo Lee, Inho Kim, Sung-Soo Yoon, et al.
Cancer Research and Treatment|December 4, 2009
Randomized, multi-center phase II trial of docetaxel plus cisplatin versus etoposide plus cisplatin as the first-line therapy for patients with advanced non-small cell lung cancerNam-Su Lee, Hee-Sook Park, Jong-Ho Won, et al.
Transfusion|December 10, 2013
Deferasirox improves hematologic and hepatic function with effective reduction of serum ferritin and liver iron concentration in transfusional iron overload patients with myelodysplastic syndrome or aplastic anemiaJune-Won Cheong, Hyeoung-Joon Kim, Kyoo-Hyung Lee, et al.
Biomed Research International|July 23, 2014
Changes in osteoblastic activity in patient who received bortezomib as second line treatment for plasma cell myeloma: a prospective multicenter studyKi-Seong Eom, Seok Jin Kim, Je-Jung Lee, et al.
Annals of Hematology|February 25, 2010
Phase IV study evaluating efficacy of escalated dose of imatinib in chronic myeloid leukemia patients showing suboptimal response to standard dose imatinibYoungil Koh, Inho Kim, Sung-Soo Yoon, et al.
American Journal of Hematology|October 19, 2012
Fludarabine, cytarabine, and attenuated-dose idarubicin (m-FLAI) combination therapy for elderly acute myeloid leukemia patientsInho Kim, Youngil Koh, Sung-Soo Yoon, et al.
Leukemia & Lymphoma|April 6, 2011
Trough plasma imatinib levels are correlated with optimal cytogenetic responses at 6 months after treatment with standard dose of imatinib in newly diagnosed chronic myeloid leukemiaSang Kyun Sohn, Suk Joong Oh, Byung Soo Kim, et al.
The Korean Journal of Internal Medicine|July 11, 2022
Long-term follow-up results of cytarabine-containing chemotherapy for acute promyelocytic leukemiaYoung Hoon Park, Dae-Young Kim, Yeung-Chul Mun, et al.
Pageof 9